WADA Declines Appeal in Iga Swiatek Doping Case

The tennis star's one-month suspension for a banned substance was deemed unintentional, clearing her to continue competing.

Iga Swiatek tested positive for trimetazidine (TMZ) in August 2024, which was traced to contaminated melatonin medication she used for sleep issues.
The International Tennis Integrity Agency (ITIA) ruled there was no significant fault or negligence on Swiatek's part, leading to a one-month suspension last year.
WADA announced it would not appeal the ITIA's decision, citing the plausibility of Swiatek's explanation and lack of scientific grounds to challenge it.
Swiatek expressed relief and satisfaction, saying the decision provides closure and allows her to focus on her tennis career, including her current run at the Australian Open.
The case has drawn comparisons to WADA's ongoing appeal of a separate doping case involving men's world No. 1 Jannik Sinner, whose hearing is scheduled for April.